{
  "company": "IQVIA Holdings",
  "ticker": "IQV",
  "period": {
    "from": "2026-03-10",
    "to": "2026-04-09",
    "days": 30
  },
  "sentiment_breakdown": {
    "positive": 27,
    "negative": 8,
    "neutral": 21
  },
  "synthesis": {
    "executive_summary": "Sentiment analysis for IQVIA Holdings (IQV) from 2026-03-10 to 2026-04-09. Analyzed 56 items across FDA and news sources.",
    "key_findings": [],
    "overall_sentiment": "neutral"
  },
  "top_positive": [
    {
      "title": "Positive Outlook for Narrow-Moat Iqvia Supported by Durable Demand, AI Innovation, and Execution",
      "date": "2026-03-31",
      "source": "alpha_vantage",
      "score": 0.991
    },
    {
      "title": "IQVIA Holdings Inc Stock: Business Model Strength and Analyst Upgrades Signal Investor Opportunities",
      "date": "2026-03-27",
      "source": "alpha_vantage",
      "score": 0.9
    },
    {
      "title": "IQVIA Holdings Inc. (IQV) Advances Clinical Research and Data Capabilities to Drive Growth",
      "date": "2026-03-10",
      "source": "news",
      "score": 0.856
    },
    {
      "title": "IQVIA Holdings Inc. stock outperforms competitors on strong trading day",
      "date": "2026-04-01",
      "source": "alpha_vantage",
      "score": 0.711
    },
    {
      "title": "IQVIA Holdings Inc. stock outperforms competitors on strong trading day",
      "date": "2026-03-30",
      "source": "alpha_vantage",
      "score": 0.711
    },
    {
      "title": "Wealth Enhancement Advisory Services LLC Purchases 9,480 Shares of IQVIA Holdings Inc. $IQV",
      "date": "2026-03-28",
      "source": "alpha_vantage",
      "score": 0.66
    },
    {
      "title": "Healthcare: Increased Clarity on Drug Pricing and Tariffs Led to a Rebound in Q1",
      "date": "2026-04-01",
      "source": "alpha_vantage",
      "score": 0.586
    },
    {
      "title": "SG Americas Securities LLC Buys 26,161 Shares of IQVIA Holdings Inc. $IQV",
      "date": "2026-03-30",
      "source": "alpha_vantage",
      "score": 0.527
    },
    {
      "title": "Invera Wealth Advisors, LLC's IQVIA Holdings Inc(IQV) Holding History",
      "date": "2026-03-27",
      "source": "alpha_vantage",
      "score": 0.494
    },
    {
      "title": "United States Bioanalytical Testing Services Market Size,",
      "date": "2026-04-08",
      "source": "alpha_vantage",
      "score": 0.421
    }
  ],
  "top_negative": [
    {
      "title": "IQVIA Holdings Forms Death Cross, Signaling Potential Bearish Trend Ahead",
      "date": "2026-03-25",
      "source": "alpha_vantage",
      "score": -0.599
    },
    {
      "title": "AI-led selloff in contract research firms may be misjudging disruption risk",
      "date": "2026-03-31",
      "source": "alpha_vantage",
      "score": -0.557
    },
    {
      "title": "Evercore Maintains IQVIA Holdings(IQV.US) With Buy Rating, Cuts Target Price to $185",
      "date": "2026-04-08",
      "source": "alpha_vantage",
      "score": -0.296
    },
    {
      "title": "IQVIA Holdings Inc. stock rises Wednesday, still underperforms market",
      "date": "2026-04-08",
      "source": "alpha_vantage",
      "score": -0.2
    },
    {
      "title": "IQVIA Holdings Inc. stock underperforms Monday when compared to competitors",
      "date": "2026-04-06",
      "source": "alpha_vantage",
      "score": -0.2
    },
    {
      "title": "IQVIA Holdings Inc. stock rises Tuesday, still underperforms market",
      "date": "2026-03-31",
      "source": "alpha_vantage",
      "score": -0.2
    },
    {
      "title": "IQVIA Holdings Inc. stock underperforms Friday when compared to competitors",
      "date": "2026-03-27",
      "source": "alpha_vantage",
      "score": -0.2
    },
    {
      "title": "Is IQVIA Holdings Stock Underperforming the Nasdaq?",
      "date": "2026-03-10",
      "source": "news",
      "score": -0.2
    }
  ],
  "raw_data": {
    "total_items": 56,
    "items": [
      {
        "source": "alpha_vantage",
        "title": "IQVIA Holdings Inc. stock rises Wednesday, still underperforms market",
        "url": "https://www.marketwatch.com/data-news/iqvia-holdings-inc-stock-rises-wednesday-still-underperforms-market-296b76aa-ea4945bdf926?mod=mw_quote_news",
        "date": "2026-04-08",
        "summary": "Shares of IQVIA Holdings Inc. rose 1.13% on Wednesday to $172.54, breaking a two-day losing streak. Despite this gain, the stock underperformed the broader market, as the S&P 500 Index increased by 2.51% and the Dow Jones Industrial Average grew by 2.85%.",
        "sentiment_score": 0.222062,
        "sentiment_label": "Somewhat-Bullish",
        "relevance_score": 0.936086,
        "sentiment": {
          "label": "negative",
          "score": -0.2,
          "confidence": 0.2
        }
      },
      {
        "source": "alpha_vantage",
        "title": "NTRA Financials: Revenue Breakdown, Margins & Competitor Comparison",
        "url": "https://intellectia.ai/en/stock/NTRA/financials",
        "date": "2026-04-08",
        "summary": "This article provides a financial analysis of Natera Inc (NTRA), detailing its revenue breakdown, profit margins, and a comparison with competitors. Natera primarily generates revenue from insurance carriers, holding a significant market share with a $29.66 billion market capitalization. It highlights the company's gross margin, operating margin, and net margin, alongside its Return on Equity, and benchmarks its gross margin against industry rivals IQV and UTHR.",
        "sentiment_score": 0.104563,
        "sentiment_label": "Neutral",
        "relevance_score": 0.619636,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Evercore Maintains IQVIA Holdings(IQV.US) With Buy Rating, Cuts Target Price to $185",
        "url": "https://www.moomoo.com/news/post/68042801/evercore-maintains-iqvia-holdings-iqvus-with-buy-rating-cuts-target",
        "date": "2026-04-08",
        "summary": "Evercore has reiterated its Buy rating on IQVIA Holdings (IQV.US) but has reduced its target price to $185. This adjustment in target price comes despite maintaining a positive outlook on the company's stock.",
        "sentiment_score": 0.13809,
        "sentiment_label": "Neutral",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "negative",
          "score": -0.296,
          "confidence": 0.3
        }
      },
      {
        "source": "alpha_vantage",
        "title": "IQVIA Holdings Inc. (IQV): Billionaire David Tepper makes minor adjustment",
        "url": "https://www.msn.com/en-us/money/topstocks/iqvia-holdings-inc-iqv-billionaire-david-tepper-makes-minor-adjustment/ar-AA20lBpc?apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1",
        "date": "2026-04-08",
        "summary": "Billionaire David Tepper's Appaloosa LP recently made a minor adjustment to its holdings in IQVIA Holdings Inc. (IQV). This move involved reducing his stake by a slight margin, impacting the overall portfolio by a minimal amount. Despite this small change, IQVIA Holdings remains a significant portion of Appaloosa's portfolio.",
        "sentiment_score": 0.040091,
        "sentiment_label": "Neutral",
        "relevance_score": 0.33989,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Baird Adjusts Price Target on IQVIA Holdings to $230 From $243, Maintains Outperform Rating",
        "url": "https://www.moomoo.com/news/post/68034880/baird-adjusts-price-target-on-iqvia-holdings-to-230-from",
        "date": "2026-04-08",
        "summary": "Baird has adjusted its price target for IQVIA Holdings (IQV) to $230, down from the previous $243. Despite this reduction, the firm has chosen to maintain its \"Outperform\" rating on the company's stock. This indicates continued confidence in IQVIA's potential, even with a revised valuation.",
        "sentiment_score": -0.24468,
        "sentiment_label": "Somewhat-Bearish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.2,
          "confidence": 0.2
        }
      },
      {
        "source": "alpha_vantage",
        "title": "United States Bioanalytical Testing Services Market Size,",
        "url": "https://www.openpr.com/news/4459769/united-states-bioanalytical-testing-services-market-size",
        "date": "2026-04-08",
        "summary": "The United States Bioanalytical Testing Services Market is projected to reach US$ 12.24 Billion by 2033, growing at a CAGR of 12.6% from 2026, driven by increased demand for complex drug development and the adoption of biologics. North America currently leads with a 40% market share. Key players like IQVIA and Labcorp are expanding capabilities to meet the rising demand fueled by R&D, clinical trials, and technological advancements in analytical methods.",
        "sentiment_score": 0.262367,
        "sentiment_label": "Somewhat-Bullish",
        "relevance_score": 0.877075,
        "sentiment": {
          "label": "positive",
          "score": 0.421,
          "confidence": 0.42
        }
      },
      {
        "source": "alpha_vantage",
        "title": "IQVIA.ai Launch With Nvidia Puts AI At Core Of Pharma Ties",
        "url": "https://www.sahmcapital.com/news/content/iqviaai-launch-with-nvidia-puts-ai-at-core-of-pharma-ties-2026-04-07",
        "date": "2026-04-08",
        "summary": "IQVIA Holdings has launched IQVIA.ai, a new AI platform developed with Nvidia, aimed at integrating healthcare-grade AI, data, and compliance for life sciences clients. The platform is already seeing adoption among several top global pharmaceutical companies, positioning IQVIA to deepen client relationships and differentiate itself in a competitive market. Investors are advised to monitor the platform's impact on contract wins, client spending, and the company's financial performance amidst pote",
        "sentiment_score": 0.339827,
        "sentiment_label": "Somewhat-Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "IQVIA Holdings Inc. (IQV): Billionaire David Tepper Makes Minor Adjustment",
        "url": "https://www.insidermonkey.com/blog/iqvia-holdings-inc-iqv-billionaire-david-tepper-makes-minor-adjustment-1732955/",
        "date": "2026-04-07",
        "summary": "Billionaire David Tepper's Appaloosa Management LP has made a minor 1.7% reduction in its IQVIA Holdings Inc. (IQV) stake in Q4 2025, now holding 280,000 shares. This adjustment follows previous reductions since Q2 2025. The company is gaining Wall Street interest due to its IQVIA.ai platform, powered by NVIDIA, and normalization of trial cancellations, contributing to a high revenue visibility through 2027.",
        "sentiment_score": 0.435996,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Citi Maintains IQVIA Holdings(IQV.US) With Hold Rating, Maintains Target Price $200",
        "url": "https://www.moomoo.com/news/post/67971546/citi-maintains-iqvia-holdings-iqvus-with-hold-rating-maintains-target",
        "date": "2026-04-07",
        "summary": "Citi has reiterated its Hold rating on IQVIA Holdings (IQV.US), maintaining a target price of $200 for the company's shares. This action indicates Citi's continued neutral outlook on IQVIA's stock performance.",
        "sentiment_score": 0.043611,
        "sentiment_label": "Neutral",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "IQVIA Holdings Inc. stock underperforms Monday when compared to competitors",
        "url": "https://www.marketwatch.com/data-news/iqvia-holdings-inc-stock-underperforms-monday-when-compared-to-competitors-ced35bad-5f39c7d7d31b?mod=mw_quote_news&gaa_at=eafs&gaa_n=AWEtsqdeqfhF888-Asc4pbjtoqkLJp-diZAgGQFKVQkMV27juLa9zl56GzlA&gaa_ts=69d49bb8&gaa_sig=KN5XGOGiYdKm0jPkkzjcmCZntZMZnEMximUeC12cHQ5VV2MN1Ikhq42qFYc4eE-ew3QI3SEbyJZWB6R9LpE-AQ%3D%3D",
        "date": "2026-04-06",
        "summary": "IQVIA Holdings Inc. (IQV) shares fell by 1.47% to $170.72 on Monday, despite an overall positive trading session for the stock market where the S&P 500 and Dow Jones Industrial Average both rose. This decline ended a four-day winning streak for the company's stock. The article highlights that IQVIA's performance underperformed its competitors on this specific trading day.",
        "sentiment_score": -0.217076,
        "sentiment_label": "Somewhat-Bearish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "negative",
          "score": -0.2,
          "confidence": 0.2
        }
      },
      {
        "source": "alpha_vantage",
        "title": "IQVIA Holdings Inc. (IQV) stock price, news, quote and history",
        "url": "https://sg.finance.yahoo.com/quote/IQV/",
        "date": "2026-04-05",
        "summary": "This Yahoo Finance page provides a comprehensive overview of IQVIA Holdings Inc. (IQV) stock, including its current price, historical data, key financial metrics, and performance against benchmarks like the S&P 500. It also details the company's business segments, analyst ratings, and allows for comparison with similar companies in the Diagnostics & Research industry. The page reflects a recent stock price of $173.26 with a slight increase and notes a \"Buy\" rating upgrade from TD Cowen.",
        "sentiment_score": 0.141632,
        "sentiment_label": "Neutral",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "IQVIA (IQV) Launches IQVIA.ai Unified Agentic AI Platform with Nvidia",
        "url": "https://www.insidermonkey.com/blog/iqvia-iqv-launches-iqvia-ai-unified-agentic-ai-platform-with-nvidia-1732342/?amp=1",
        "date": "2026-04-05",
        "summary": "IQVIA Holdings Inc. (NYSE: IQV) has launched IQVIA.ai, a unified agentic AI platform developed in collaboration with Nvidia, designed for the life sciences industry. The platform aims to enhance operational efficiency and decision-making across clinical, commercial, and real-world domains by integrating IQVIA’s healthcare-grade AI and data assets with Nvidia’s advanced technology. This system, already being adopted by top pharmaceutical companies, allows for the orchestration of tasks across mul",
        "sentiment_score": 0.444658,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.382,
          "confidence": 0.38
        }
      },
      {
        "source": "alpha_vantage",
        "title": "IQVIA (IQV) Launches IQVIA.ai Unified Agentic AI Platform with Nvidia",
        "url": "https://sg.finance.yahoo.com/news/iqvia-iqv-launches-iqvia-ai-183121755.html",
        "date": "2026-04-05",
        "summary": "IQVIA Holdings Inc. (IQV) has launched IQVIA.ai, a new unified agentic AI platform developed in collaboration with Nvidia, specifically designed for the life sciences industry. This platform aims to enhance operational efficiency and decision-making across clinical, commercial, and real-world domains by integrating IQVIA's healthcare-grade AI and data with Nvidia's advanced technology. Many top pharmaceutical companies have already incorporated IQVIA's agents into their workflows, and the platfo",
        "sentiment_score": 0.442436,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.382,
          "confidence": 0.38
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Illumina (Nasdaq:ILMN) - Stock Analysis",
        "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ilmn/illumina",
        "date": "2026-04-05",
        "summary": "This Simply Wall St report provides an in-depth stock analysis of Illumina (Nasdaq:ILMN), evaluating its valuation, future growth, past performance, financial health, dividends, management, and ownership. The analysis highlights that Illumina is trading below its estimated fair value, with earnings projected to grow, and the company recently became profitable. Various analyst narratives present differing views on the company's future, focusing on clinical genomics expansion, competitive challeng",
        "sentiment_score": 0.12515,
        "sentiment_label": "Neutral",
        "relevance_score": 0.624899,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Citigroup Maintains IQVIA Holdings (IQV) Neutral Recommendation",
        "url": "http://www.msn.com/en-us/money/savingandinvesting/citigroup-maintains-iqvia-holdings-iqv-neutral-recommendation/ar-AA1PtfZL?apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1",
        "date": "2026-04-05",
        "summary": "Citigroup has reiterated its Neutral rating for IQVIA Holdings (IQV). This indicates that the analyst firm believes the stock is currently fairly valued and does not expect significant upward or downward price movements in the near future. Investors should consider this perspective when evaluating IQVIA Holdings.",
        "sentiment_score": 0.014322,
        "sentiment_label": "Neutral",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Aberdeen Group plc Has $43.44 Million Stake in IQVIA Holdings Inc. $IQV",
        "url": "https://www.marketbeat.com/instant-alerts/filing-aberdeen-group-plc-has-4344-million-stake-in-iqvia-holdings-inc-iqv-2026-04-05/",
        "date": "2026-04-05",
        "summary": "Aberdeen Group plc significantly increased its stake in IQVIA Holdings Inc. by 39.6% in Q4, bringing its total holding to 192,696 shares valued at $43.44 million. Other institutional investors also adjusted their positions in the medical research company. IQVIA exceeded Q4 earnings expectations with $3.42 EPS and 10.3% year-over-year revenue growth, leading analysts to maintain an average \"Buy\" rating with an average target price of $229.13.",
        "sentiment_score": 0.314412,
        "sentiment_label": "Somewhat-Bullish",
        "relevance_score": 0.963396,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Revvity, Inc. (RVTY) stock price, news, quote and history",
        "url": "https://uk.finance.yahoo.com/quote/RVTY/",
        "date": "2026-04-03",
        "summary": "This Yahoo Finance page provides comprehensive financial information for Revvity, Inc. (RVTY), including its current stock price, dividend announcements, historical performance data, and key metrics. It also offers an overview of the company's health sciences solutions, its market position in diagnostics and research, and analyst insights. The page enables users to compare RVTY with similar companies in the Diagnostics & Research industry.",
        "sentiment_score": 0.044624,
        "sentiment_label": "Neutral",
        "relevance_score": 0.602105,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "HF Advisory Group LLC Buys 146,444 Shares of IQVIA Holdings Inc. $IQV",
        "url": "https://www.marketbeat.com/instant-alerts/filing-hf-advisory-group-llc-buys-146444-shares-of-iqvia-holdings-inc-iqv-2026-04-02/",
        "date": "2026-04-02",
        "summary": "HF Advisory Group LLC significantly increased its stake in IQVIA Holdings Inc. by 1,791.6% in Q4, acquiring 146,444 shares to hold a total of 154,618 shares valued at approximately $34.85 million. This makes IQVIA the fund's 11th largest position. The medical research company currently holds a consensus \"Buy\" rating from analysts with an average price target of $229.13, and recently reported strong quarterly earnings, surpassing analyst estimates for both EPS and revenue.",
        "sentiment_score": 0.394634,
        "sentiment_label": "Bullish",
        "relevance_score": 0.951692,
        "sentiment": {
          "label": "positive",
          "score": 0.296,
          "confidence": 0.3
        }
      },
      {
        "source": "alpha_vantage",
        "title": "VNRX|VolitionRX Ltd|Price:0.200|Chg%:-0.00",
        "url": "https://www.tradingkey.com/markets/stocks/nasdaq-vnrx/stock-analysis",
        "date": "2026-04-02",
        "summary": "VolitionRX Ltd (VNRX) shows weak fundamentals but high growth potential, with its revenue growing an average of 122.80% year-on-year over the past three years. The stock is considered fairly valued within its industry, despite a recent 14.25% drop and a current analyst \"Buy\" rating with upside potential of over 900%. Institutional ownership is high, though holdings decreased by 21.74% last quarter.",
        "sentiment_score": 0.307395,
        "sentiment_label": "Somewhat-Bullish",
        "relevance_score": 0.572542,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Healthcare: Increased Clarity on Drug Pricing and Tariffs Led to a Rebound in Q1",
        "url": "https://www.morningstar.com/stocks/healthcare-increased-clarity-drug-pricing-tariffs-led-rebound-q1",
        "date": "2026-04-01",
        "summary": "The Morningstar Healthcare Index, after lagging due to drug pricing uncertainty and tariffs, is expected to see solid performance in 2026, driven by its defensive nature, innovation, and benefits from AI. The sector is considered undervalued overall, with healthcare plans and devices looking most attractive. AI is anticipated to significantly reduce the time required to bring new pharmaceuticals to market, benefiting biopharma.",
        "sentiment_score": 0.34106,
        "sentiment_label": "Somewhat-Bullish",
        "relevance_score": 0.829253,
        "sentiment": {
          "label": "positive",
          "score": 0.586,
          "confidence": 0.59
        }
      },
      {
        "source": "alpha_vantage",
        "title": "IQVIA Holdings Inc. stock outperforms competitors on strong trading day",
        "url": "https://www.marketwatch.com/data-news/iqvia-holdings-inc-stock-outperforms-competitors-on-strong-trading-day-50b7ce0e-58555164c769?mod=mw_quote_news&gaa_at=eafs&gaa_n=AWEtsqf81i66v5NvTbMnPpiZ33lHKUZOEBRe4O3geGjI3IveXwUjR8KFY9ej&gaa_ts=69ce1957&gaa_sig=uF9-YbsCywYHUAA_oBPTCFHe0ojRLe4w_yvArKQ-dyARnJNFpm7CyeHZEiC0vtL-zAazv480PWqweEGa1ubkaA%3D%3D",
        "date": "2026-04-01",
        "summary": "IQVIA Holdings Inc. (IQV) stock rose 1.09% to $172.40 on Wednesday, outperforming the broader market. The S&P 500 Index and Dow Jones Industrial Average also saw gains, rising 0.72% and 0.48% respectively. This marks the third consecutive day of gains for IQVIA Holdings.",
        "sentiment_score": 0.419208,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.711,
          "confidence": 0.71
        }
      },
      {
        "source": "alpha_vantage",
        "title": "IQVIA Holdings Inc. $IQV Stake Lifted by J. Safra Sarasin Holding AG",
        "url": "https://www.marketbeat.com/instant-alerts/filing-iqvia-holdings-inc-iqv-stake-lifted-by-j-safra-sarasin-holding-ag-2026-04-01/",
        "date": "2026-04-01",
        "summary": "J. Safra Sarasin Holding AG significantly increased its stake in IQVIA Holdings Inc. by 174.3% in the fourth quarter, now owning 12,827 shares valued at $2.89 million. Several other institutional investors also adjusted their holdings, with a large percentage of IQVIA stock owned by hedge funds. Analysts have issued varied ratings, but the company generally holds a \"Buy\" consensus with an average target price of $229.13.",
        "sentiment_score": 0.327627,
        "sentiment_label": "Somewhat-Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Positive Outlook for Narrow-Moat Iqvia Supported by Durable Demand, AI Innovation, and Execution",
        "url": "https://www.morningstar.com/company-reports/1463752-positive-outlook-for-narrow-moat-iqvia-supported-by-durable-demand-ai-innovation-and-execution",
        "date": "2026-03-31",
        "summary": "Iqvia, formed from the merger of Quintiles and IMS Health, is a leader in contract research organizations and life sciences data. The company benefits from durable demand, AI innovation, and strong execution. This positive outlook is supported by its strong position in real-world evidence and robust business strategy.",
        "sentiment_score": 0.468747,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.991,
          "confidence": 0.99
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Progyny (NASDAQ: PGNY) schedules virtual 2026 meeting; board, audit ratification on ballot",
        "url": "https://www.stocktitan.net/sec-filings/PGNY/pre-14a-progyny-inc-preliminary-proxy-statement-55f7fc59e4a7.html",
        "date": "2026-03-31",
        "summary": "Progyny (NASDAQ: PGNY) has scheduled its 2026 virtual annual meeting for May 21, 2026, with a record date of March 27, 2026, and 78.3 million shares outstanding. Stockholders will vote on the election of three Class I directors, ratification of Ernst & Young LLP as the independent auditor, an advisory vote on executive compensation, and two amendments to the Certificate of Incorporation to eliminate certain supermajority voting requirements. The proposed amendments aim to streamline governance b",
        "sentiment_score": 0.000453,
        "sentiment_label": "Neutral",
        "relevance_score": 0.68132,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "IQVIA Holdings Inc. stock rises Tuesday, still underperforms market",
        "url": "https://www.marketwatch.com/data-news/iqvia-holdings-inc-stock-rises-tuesday-still-underperforms-market-7ed58b48-8be52711e922?gaa_at=eafs&gaa_n=AWEtsqdkg4GWRubztghb9qzn9GPls8JncW-HR4U_W01zwVLK23I93XDLDG-g&gaa_ts=69ccb2bd&gaa_sig=IcMs0idqDaoE01uQbOwzExZGjbPDOvwQa3Ca17tVo_6gfR9Kg6ehBx3A904friBl3eRRLJGpfcyjZIZcE5ahEw%3D%3D",
        "date": "2026-03-31",
        "summary": "IQVIA Holdings Inc. (IQV) saw its stock rise by 2.64% on Tuesday, closing at $170.54. Despite this gain, the company's performance underperformed the broader market, which experienced a favorable trading session with the S&P 500 Index and Dow Jones Industrial Average rising more significantly. This marked the second consecutive day of gains for IQVIA stock.",
        "sentiment_score": 0.194928,
        "sentiment_label": "Somewhat-Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "negative",
          "score": -0.2,
          "confidence": 0.2
        }
      },
      {
        "source": "alpha_vantage",
        "title": "195,165 Shares in IQVIA Holdings Inc. $IQV Purchased by Vaughan Nelson Investment Management L.P.",
        "url": "https://www.marketbeat.com/instant-alerts/filing-195165-shares-in-iqvia-holdings-inc-iqv-purchased-by-vaughan-nelson-investment-management-lp-2026-03-31/",
        "date": "2026-03-31",
        "summary": "Vaughan Nelson Investment Management L.P. recently purchased 195,165 shares of IQVIA Holdings Inc. (NYSE:IQV) stock, valued at approximately $43.99 million, representing a new stake in the company. Other institutional investors have also adjusted their holdings in IQVIA. Analysts generally rate IQVIA as a \"Buy\" with a consensus price target of $229.13, following strong Q4 earnings where the company beat estimates and provided positive FY2026 guidance.",
        "sentiment_score": 0.495002,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.296,
          "confidence": 0.3
        }
      },
      {
        "source": "alpha_vantage",
        "title": "AI-led selloff in contract research firms may be misjudging disruption risk",
        "url": "https://www.sahmcapital.com/news/content/ai-led-selloff-in-contract-research-firms-may-be-misjudging-disruption-risk-2026-03-31",
        "date": "2026-03-31",
        "summary": "Shares of contract research organizations (CROs) have dropped due to fears that AI advancements could allow drugmakers to conduct clinical trials in-house. However, industry experts and analysts argue that the selloff overestimates AI's ability to replace CROs' core services, such as global patient recruitment and trial execution, suggesting that AI is more likely to enhance efficiency rather than disrupt the sector. While investors are concerned, analysts believe there's no evidence of pharma c",
        "sentiment_score": 0.213933,
        "sentiment_label": "Somewhat-Bullish",
        "relevance_score": 0.843934,
        "sentiment": {
          "label": "negative",
          "score": -0.557,
          "confidence": 0.56
        }
      },
      {
        "source": "alpha_vantage",
        "title": "IQVIA Holdings Inc. stock outperforms competitors on strong trading day",
        "url": "https://www.marketwatch.com/data-news/iqvia-holdings-inc-stock-outperforms-competitors-on-strong-trading-day-09d2bbde-8f34dadb5fa6?mod=mw_quote_news&gaa_at=eafs&gaa_n=AWEtsqcwfreGoQnhWhu6rQxA27XM3I6Fh5Q6TT5gzXY2xERyhqp26ign8Q-m&gaa_ts=69cb6f3f&gaa_sig=3F9k_D6LL2qrSQRkz_tpnlCxCPM5elKjxlC1J_IbbfHeEq018I3lGg1tLkrMYLFG5b_ptBK0THlNCPDUb0Da6Q%3D%3D",
        "date": "2026-03-30",
        "summary": "Shares of IQVIA Holdings Inc. (IQV) rose 1.41% to $166.16 on Monday, outperforming the broader market. This occurred during a mixed trading session where the Dow Jones Industrial Average saw a slight increase, while the S&P 500 Index declined. The company's stock is currently 32.74% below its 52-week high.",
        "sentiment_score": 0.428652,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.711,
          "confidence": 0.71
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Behavioral Patterns of IQV and Institutional Flows - Stock Traders Daily",
        "url": "https://news.stocktradersdaily.com/news_release/98/Behavioral_Patterns_of_IQV_and_Institutional_Flows_033026075201_1774914721.html",
        "date": "2026-03-30",
        "summary": "This article analyzes Iqvia Holdings Inc. (NYSE: IQV) using AI models to identify behavioral patterns and institutional trading flows. It suggests a weak near and mid-term sentiment, potentially challenging a long-term positive outlook, and outlines specific trading strategies (position, momentum, and risk hedging) with detailed entry, target, and stop-loss levels based on different risk profiles. The analysis also provides multi-timeframe signal strengths and support/resistance levels for the s",
        "sentiment_score": -0.249814,
        "sentiment_label": "Somewhat-Bearish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "IQVIA Holdings Inc (IQV) Shares Gap Down to $163.85 on Mar 30",
        "url": "https://www.gurufocus.com/news/8756831/iqvia-holdings-inc-iqv-shares-gap-down-to-16385-on-mar-30?mobile=true",
        "date": "2026-03-30",
        "summary": "IQVIA Holdings Inc (IQV) shares fell 3.28% in mid-day trading on March 30, reaching an intraday low of $162.36 before closing at $163.85. This puts the stock significantly below its 52-week high, while analysts maintain an \"Outperform\" rating with an average target price implying a 44.47% upside. GuruFocus' estimated fair value (GF Value) suggests an even greater potential upside of 60.57%.",
        "sentiment_score": -0.245433,
        "sentiment_label": "Somewhat-Bearish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.296,
          "confidence": 0.3
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Truist Financial Maintains IQVIA Holdings(IQV.US) With Buy Rating",
        "url": "https://www.moomoo.com/news/post/67626416/truist-financial-maintains-iqvia-holdings-iqvus-with-buy-rating",
        "date": "2026-03-30",
        "summary": "Truist Financial has reaffirmed its Buy rating on IQVIA Holdings (IQV.US). This indicates a continued positive outlook from the financial institution regarding the company's stock performance.",
        "sentiment_score": 0.402376,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "SG Americas Securities LLC Buys 26,161 Shares of IQVIA Holdings Inc. $IQV",
        "url": "https://www.marketbeat.com/instant-alerts/filing-sg-americas-securities-llc-buys-26161-shares-of-iqvia-holdings-inc-iqv-2026-03-30/",
        "date": "2026-03-30",
        "summary": "SG Americas Securities LLC increased its stake in IQVIA Holdings Inc. by 108.8% in Q4, acquiring an additional 26,161 shares, bringing its total to 50,206 shares valued at $11.32 million. IQVIA reported strong Q4 earnings, beating analyst estimates with EPS of $3.42 and revenue of $4.36 billion, and provided positive FY2026 guidance. Wall Street analysts maintain a \"Buy\" consensus rating for IQVIA, with an average target price of $229.13.",
        "sentiment_score": 0.40422,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.527,
          "confidence": 0.53
        }
      },
      {
        "source": "alpha_vantage",
        "title": "GSK’s hepatitis B drug accepted for China regulatory review",
        "url": "https://www.investing.com/news/company-news/gsks-hepatitis-b-drug-accepted-for-china-regulatory-review-93CH-4586716",
        "date": "2026-03-30",
        "summary": "GSK announced that China's National Medical Products Administration has accepted a new drug application for bepirovirsen, its investigational treatment for chronic hepatitis B. This submission is supported by positive Phase III clinical trial results showing statistically significant functional cure rates. The drug aims to address the significant health burden of chronic hepatitis B, which affects millions in China and worldwide.",
        "sentiment_score": 0.243197,
        "sentiment_label": "Somewhat-Bullish",
        "relevance_score": 0.621865,
        "sentiment": {
          "label": "positive",
          "score": 0.273,
          "confidence": 0.27
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Wealth Enhancement Advisory Services LLC Purchases 9,480 Shares of IQVIA Holdings Inc. $IQV",
        "url": "https://www.marketbeat.com/instant-alerts/filing-wealth-enhancement-advisory-services-llc-purchases-9480-shares-of-iqvia-holdings-inc-iqv-2026-03-28/",
        "date": "2026-03-28",
        "summary": "Wealth Enhancement Advisory Services LLC has increased its stake in IQVIA Holdings Inc. by 35.8%, acquiring an additional 9,480 shares and bringing its total holdings to 35,960 shares valued at $8.674 million. IQVIA currently holds a consensus \"Buy\" rating with a price target of $229.13 and recently surpassed quarterly earnings expectations. The company also issued a positive FY2026 EPS guidance of $12.55–$12.85.",
        "sentiment_score": 0.461819,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.66,
          "confidence": 0.66
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Eagle Rock Investment Company LLC Buys 14,084 Shares of IQVIA Holdings Inc. $IQV",
        "url": "https://www.marketbeat.com/instant-alerts/filing-eagle-rock-investment-company-llc-buys-14084-shares-of-iqvia-holdings-inc-iqv-2026-03-28/",
        "date": "2026-03-28",
        "summary": "Eagle Rock Investment Company LLC increased its stake in IQVIA Holdings Inc. (NYSE:IQV) by 30.4% in the fourth quarter, acquiring an additional 14,084 shares and bringing their total holdings to 60,416 shares valued at $13.62 million. Other institutional investors also adjusted their positions in IQV. Several Wall Street analysts have issued \"Buy\" or \"Overweight\" ratings for IQVIA, with an average price target of $229.13.",
        "sentiment_score": 0.416272,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.296,
          "confidence": 0.3
        }
      },
      {
        "source": "alpha_vantage",
        "title": "TD Cowen upgrades IQVIA (IQV) to buy and raises price target to $213",
        "url": "http://www.msn.com/en-us/money/topstocks/td-cowen-upgrades-iqvia-iqv-to-buy-and-raises-price-target-to-213/ar-AA1ZiJKO?apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1",
        "date": "2026-03-27",
        "summary": "TD Cowen has upgraded IQVIA (IQV) to a \"buy\" rating and increased its price target to $213. This upgrade reflects a positive outlook on the company's financial prospects and market position. The revised price target suggests a significant upside potential for IQVIA's stock.",
        "sentiment_score": 0.443231,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.2,
          "confidence": 0.2
        }
      },
      {
        "source": "alpha_vantage",
        "title": "IQVIA Holdings Inc. stock underperforms Friday when compared to competitors",
        "url": "https://www.marketwatch.com/data-news/iqvia-holdings-inc-stock-underperforms-friday-when-compared-to-competitors-8ead1f3c-074eaa0da08e?mod=mw_quote_news&gaa_at=eafs&gaa_n=AWEtsqejRuGIxbWxjCCr0y-0qvJaoLYLIb4-x_16oIuyk6D8Y2YPo559z5ak&gaa_ts=69c773b6&gaa_sig=rEqRwe-25x1IVNKLzUTPbdAcF4Bhf3EAyc7pfv1MJr6dzqL8HcFyWwCUhUCu8xdMcJ3JSxRIJX_o-0CVFfsgMA%3D%3D",
        "date": "2026-03-27",
        "summary": "IQVIA Holdings Inc. (IQV) stock fell 3.28% on Friday, closing at $163.85, a day when the broader market also experienced declines with the S&P 500 down 1.67% and the Dow Jones Industrial Average down 1.73%. This performance places IQVIA Holdings Inc. 33.68% below its 52-week high of $247.05, reached on January 9th. The article highlights the stock's underperformance relative to major indices.",
        "sentiment_score": -0.449883,
        "sentiment_label": "Bearish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "negative",
          "score": -0.2,
          "confidence": 0.2
        }
      },
      {
        "source": "alpha_vantage",
        "title": "A Look At IQVIA Holdings (IQV) Valuation After The IQVIA.ai Launch With NVIDIA And Analyst Upgrades",
        "url": "https://www.sahmcapital.com/news/content/a-look-at-iqvia-holdings-iqv-valuation-after-the-iqviaai-launch-with-nvidia-and-analyst-upgrades-2026-03-28",
        "date": "2026-03-27",
        "summary": "IQVIA Holdings (IQV) recently launched IQVIA.ai in collaboration with NVIDIA, aiming to integrate AI into life sciences workflows. Despite this launch and analyst upgrades, the stock has seen declines over 1 day, 90 days, and 1 year, trading at $163.85. Simply Wall St's \"Most Popular Narrative\" suggests the stock is 34.5% undervalued with a fair value of $250 per share, attributing this to future earnings power and AI-driven efficiency, though it acknowledges potential challenges from pricing pr",
        "sentiment_score": 0.29804,
        "sentiment_label": "Somewhat-Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.2,
          "confidence": 0.2
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Vanguard (IQV) Amendment 13G/A: reports 0 shares after realignment",
        "url": "https://www.stocktitan.net/sec-filings/IQV/schedule-13g-a-iqvia-holdings-inc-amended-passive-investment-disclosu-ca3ac4657526.html",
        "date": "2026-03-27",
        "summary": "The Vanguard Group filed an Amendment No. 11 to a Schedule 13G/A for IQVIA Holdings Inc., reporting beneficial ownership of 0 shares of Common Stock, representing 0% of the class. This change is due to an internal realignment completed on January 12, 2026, where certain subsidiaries will now report beneficial ownership separately. The filing confirms Vanguard no longer holds, or is deemed to hold, beneficial ownership over these securities.",
        "sentiment_score": 0.046363,
        "sentiment_label": "Neutral",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.296,
          "confidence": 0.3
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Invera Wealth Advisors, LLC's IQVIA Holdings Inc(IQV) Holding History",
        "url": "https://www.gurufocus.com/guru-portfolio/Invera%20Wealth%20Advisors,%20LLC/IQV",
        "date": "2026-03-27",
        "summary": "This article details Invera Wealth Advisors, LLC's historical holdings in IQVIA Holdings Inc (IQV) as of December 31, 2025. It shows that Invera Wealth Advisors holds 10,537 shares valued at $2.38 million, representing 1.5% of their portfolio. The firm has made 3 purchases and 5 sales of IQV shares since Q4 2023, resulting in an estimated loss of -15.07% on their current holdings.",
        "sentiment_score": -0.115308,
        "sentiment_label": "Neutral",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.494,
          "confidence": 0.49
        }
      },
      {
        "source": "alpha_vantage",
        "title": "IQVIA Holdings Inc Stock: Business Model Strength and Analyst Upgrades Signal Investor Opportunities",
        "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/iqvia-holdings-inc-stock-business-model-strength-and-analyst-upgrades/69004027",
        "date": "2026-03-27",
        "summary": "IQVIA Holdings Inc (IQV) is highlighted as a global leader in healthcare intelligence, benefiting from a recent Barclays upgrade to overweight with a $210 target price. The company's strong business model leverages vast datasets and AI-driven insights in clinical research and R&D solutions, positioning it well amid rising demand for real-world evidence and personalized medicine. North American investors are encouraged to consider IQV for its resilient healthcare exposure and predictable cash flo",
        "sentiment_score": 0.406662,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.9,
          "confidence": 0.9
        }
      },
      {
        "source": "alpha_vantage",
        "title": "IQVIA Holdings Inc. (NYSE:IQV) Given Average Rating of \"Buy\" by Brokerages",
        "url": "https://www.marketbeat.com/instant-alerts/iqvia-holdings-inc-nyseiqv-given-average-rating-of-buy-by-brokerages-2026-03-27/",
        "date": "2026-03-27",
        "summary": "IQVIA Holdings Inc. (NYSE:IQV) has received an average \"Buy\" rating from seventeen brokerages, with an average 12-month price target of $229.13. The medical research company recently exceeded quarterly earnings and revenue estimates and set a positive FY 2026 EPS guidance. Institutional investors hold a significant stake in IQVIA, with shares currently trading at $169.05, representing a market capitalization of approximately $28.7 billion.",
        "sentiment_score": 0.416161,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "IQV SEC Filings - Iqvia Hldgs Inc 10-K, 10-Q, 8-K Forms",
        "url": "https://www.stocktitan.net/sec-filings/IQV/page-3.html",
        "date": "2026-03-26",
        "summary": "This page provides comprehensive access to IQVIA Holdings Inc. (IQV) SEC filings, including 10-K, 10-Q, 8-K forms, and insider trading reports. It highlights recent insider transactions where executives received performance-based shares and disposed of others, often to cover tax obligations. The platform also offers AI-powered summaries of these filings to help investors understand key corporate developments and financial information.",
        "sentiment_score": 0.006234,
        "sentiment_label": "Neutral",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Earnings call transcript: OptimizeRx Q4 2025 earnings beat forecasts, stock dips",
        "url": "https://m.investing.com/news/transcripts/earnings-call-transcript-optimizerx-q4-2025-earnings-beat-forecasts-stock-dips-93CH-4581514?ampMode=1",
        "date": "2026-03-26",
        "summary": "OptimizeRx (OPRX) reported strong financial results for Q4 2025, with EPS of $0.51 and revenue of $32.2 million, both exceeding forecasts. Despite the earnings beat and a record gross margin of 74.8%, the stock declined 14.36% in after-hours trading, potentially due to broader market conditions or investor concerns about future normalized margins. The company provided 2026 guidance with revenue between $109 million-$114 million and adjusted EBITDA between $21 million-$25 million, reflecting a mo",
        "sentiment_score": 0.108934,
        "sentiment_label": "Neutral",
        "relevance_score": 0.642679,
        "sentiment": {
          "label": "positive",
          "score": 0.2,
          "confidence": 0.2
        }
      },
      {
        "source": "alpha_vantage",
        "title": "IQV SEC Filings - Iqvia Hldgs Inc 10-K, 10-Q, 8-K Forms",
        "url": "https://www.stocktitan.net/sec-filings/IQV/page-5.html",
        "date": "2026-03-25",
        "summary": "This page provides a comprehensive resource for IQVIA Holdings Inc. (IQV) SEC filings, including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms. It highlights recent filings from October and November 2025, detailing director share acquisitions, executive stock appreciation rights exercises and sales, board appointments, and the company's Q3 2025 financial results. The platform, Stock Titan, offers AI-powered summaries and sentiment analysis for these",
        "sentiment_score": 0.277609,
        "sentiment_label": "Somewhat-Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Is IQVIA.ai’s NVIDIA‑Powered Platform Altering The Investment Case For IQVIA Holdings (IQV)?",
        "url": "https://www.sahmcapital.com/news/content/is-iqviaais-nvidiapowered-platform-altering-the-investment-case-for-iqvia-holdings-iqv-2026-03-24",
        "date": "2026-03-25",
        "summary": "IQVIA Holdings recently launched IQVIA.ai, an NVIDIA-powered AI platform designed to embed healthcare-grade AI into life sciences workflows. This platform, along with an expanded partnership with Salesforce, aims to strengthen IQVIA's data and AI integration within pharmaceutical processes and reinforce switching costs. While the new platform offers AI-enabled differentiation, analysts note that intense CRO competition and pricing pressures remain significant risks to IQVIA's investment narrativ",
        "sentiment_score": 0.255428,
        "sentiment_label": "Somewhat-Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "IQVIA Holdings Forms Death Cross, Signaling Potential Bearish Trend Ahead",
        "url": "https://www.marketsmojo.com/news/stocks-in-action/iqvia-holdings-forms-death-cross-signaling-potential-bearish-trend-ahead-3911291",
        "date": "2026-03-25",
        "summary": "IQVIA Holdings, Inc. has experienced a \"Death Cross\" technical event, where its short-term moving average fell below its long-term moving average, signaling potential bearish momentum. The stock has significantly underperformed the S&P 500 over the past year and year-to-date, indicating a challenging market position and potential for further declines.",
        "sentiment_score": -0.610923,
        "sentiment_label": "Bearish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "negative",
          "score": -0.599,
          "confidence": 0.6
        }
      },
      {
        "source": "alpha_vantage",
        "title": "IQVIA Holdings Inc. $IQV Stock Position Decreased by Assenagon Asset Management S.A.",
        "url": "https://www.marketbeat.com/instant-alerts/filing-iqvia-holdings-inc-iqv-stock-position-decreased-by-assenagon-asset-management-sa-2026-03-25/",
        "date": "2026-03-25",
        "summary": "Assenagon Asset Management S.A. reduced its stake in IQVIA Holdings Inc. (NYSE:IQV) by 8.7% during the fourth quarter, selling 21,374 shares. Despite this, other institutional investors increased their positions in IQVIA. The medical research company has an average \"Buy\" rating from analysts with an average price target of $229.13, and recently beat earnings estimates for the latest quarter.",
        "sentiment_score": 0.109501,
        "sentiment_label": "Neutral",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.361,
          "confidence": 0.36
        }
      },
      {
        "source": "alpha_vantage",
        "title": "ICON, Advarra Partner on Connected Site Network Model",
        "url": "https://www.contractpharma.com/breaking-news/icon-advarra-partner-on-connected-site-network-model/",
        "date": "2026-03-24",
        "summary": "ICON plc and Advarra have formed a strategic partnership to develop a \"research-ready\" connected site network model for clinical trials. This collaboration aims to integrate ICON’s global clinical trial services with Advarra’s site systems, including CTMSs, eISF, and eSource, to streamline operations. The goal is to reduce administrative burdens, accelerate study startup, and improve overall clinical trial participation and efficiency by leveraging Advarra's operational intelligence platform.",
        "sentiment_score": 0.29562,
        "sentiment_label": "Somewhat-Bullish",
        "relevance_score": 0.64586,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "TD Cowen upgrades IQVIA (IQV) to buy and raises price target to $213",
        "url": "https://www.msn.com/en-us/money/topstocks/td-cowen-upgrades-iqvia-iqv-to-buy-and-raises-price-target-to-213/ar-AA1ZiJKO?ocid=finance-verthp-feeds",
        "date": "2026-03-24",
        "summary": "TD Cowen has upgraded its rating for IQVIA (IQV) from market perform to buy. The firm also increased its price target for IQV shares to $213. This indicates a positive outlook on the company's future performance by TD Cowen.",
        "sentiment_score": 0.405199,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.2,
          "confidence": 0.2
        }
      },
      {
        "source": "news",
        "source_name": "Yahoo Entertainment",
        "title": "IQVIA Holdings Inc. (IQV): Billionaire David Tepper Makes Minor Adjustment",
        "description": "",
        "url": "https://consent.yahoo.com/v2/collectConsent?sessionId=1_cc-session_aca927a4-f5a6-41e8-a121-330b5bf66fde",
        "date": "2026-04-07",
        "published_at": "2026-04-07T14:28:03Z",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "news",
        "source_name": "GlobeNewswire",
        "title": "Dermatomyositis Global Clinical Trials Market Review Report 2026: Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End Point Status",
        "description": "The clinical trial report highlights opportunities in Dermatomyositis trials by revealing key trends in trial phases, sponsor types, and regions, particularly in G7 and E7 countries. It aids strategic decision-making by identifying prime trial locations and o…",
        "url": "https://www.globenewswire.com/news-release/2026/04/07/3269299/28124/en/Dermatomyositis-Global-Clinical-Trials-Market-Review-Report-2026-Region-Country-G7-E7-Trial-Status-Trial-Phase-Sponsor-Type-and-End-Point-Status.html",
        "date": "2026-04-07",
        "published_at": "2026-04-07T13:28:00Z",
        "sentiment": {
          "label": "positive",
          "score": 0.382,
          "confidence": 0.38
        }
      },
      {
        "source": "news",
        "source_name": "Yahoo Entertainment",
        "title": "IQVIA (IQV) Launches IQVIA.ai Unified Agentic AI Platform with Nvidia",
        "description": "",
        "url": "https://consent.yahoo.com/v2/collectConsent?sessionId=1_cc-session_14b688ee-99d8-45eb-830b-c9df2dca0d5d",
        "date": "2026-04-05",
        "published_at": "2026-04-05T18:31:21Z",
        "sentiment": {
          "label": "positive",
          "score": 0.382,
          "confidence": 0.38
        }
      },
      {
        "source": "news",
        "source_name": "Yahoo Entertainment",
        "title": "TD Cowen Upgrades IQVIA (IQV) to Buy and Raises Price Target to $213",
        "description": "",
        "url": "https://consent.yahoo.com/v2/collectConsent?sessionId=1_cc-session_0f826ad2-de99-47c1-afef-222a2c734ee3",
        "date": "2026-03-24",
        "published_at": "2026-03-24T14:43:11Z",
        "sentiment": {
          "label": "positive",
          "score": 0.2,
          "confidence": 0.2
        }
      },
      {
        "source": "news",
        "source_name": "Yahoo Entertainment",
        "title": "IQVIA Holdings Inc. (IQV) Advances Clinical Research and Data Capabilities to Drive Growth",
        "description": "IQVIA Holdings Inc. (NYSE:IQV) is one of the 11 Best Affordable Growth Stocks to Buy Now. On March 3, analysts at RBC Capital initiated coverage of IQVIA...",
        "url": "https://finance.yahoo.com/news/iqvia-holdings-inc-iqv-advances-183828418.html",
        "date": "2026-03-10",
        "published_at": "2026-03-10T18:38:28Z",
        "sentiment": {
          "label": "positive",
          "score": 0.856,
          "confidence": 0.86
        }
      },
      {
        "source": "news",
        "source_name": "Yahoo Entertainment",
        "title": "Is IQVIA Holdings Stock Underperforming the Nasdaq?",
        "description": "",
        "url": "https://consent.yahoo.com/v2/collectConsent?sessionId=1_cc-session_8e570186-ab6b-4559-8f61-50c8109d77b1",
        "date": "2026-03-10",
        "published_at": "2026-03-10T14:01:35Z",
        "sentiment": {
          "label": "negative",
          "score": -0.2,
          "confidence": 0.2
        }
      }
    ]
  }
}